相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
招募中
1
100.0%
暂无批准数据
- CryoTherapeutics has treated the first patient in its ICECAP clinical trial, evaluating localized cryotherapy to stabilize high-risk coronary plaques before they cause myocardial infarction. - The first enrolled patient had stable angina and was identified with a non-obstructive high-risk coronary plaque using coronary CT imaging and AI-enabled plaque characterization tools. - The ICECAP study employs a multimodal imaging strategy combining NIRS and DeepOCT to confirm plaque morphology and guide cryotherapy delivery at temperatures of -10 to -20°C. - The trial brings together collaborators including the Cardiovascular Research Foundation, HeartFlow, and Medis Medical Imaging, with recruitment expanding to up to five centers across Belgium and the United Kingdom.
- CryoTherapeutics has partnered with SpectraWAVE and the Cardiovascular Research Foundation to launch the ICECAP clinical study, targeting non-obstructive high-risk coronary plaques with localized cryotherapy. - The trial will use a multimodal imaging approach combining Near-Infrared Spectroscopy and next-generation Optical Coherence Tomography with AI-assisted analysis to assess plaque stabilization effects. - Patient recruitment is expected to begin in Q1 2026 across up to five centers in Belgium and the United Kingdom, building on encouraging safety results from the previous POLARSTAR Study. - The innovative approach aims to prevent myocardial infarction by stabilizing vulnerable plaques through temporary cooling to -10°C to -20°C without permanent implants.
- The Cardiovascular Research Foundation announced 28 cutting-edge clinical trials for TCT 2025, scheduled October 25-28 in San Francisco, focusing on minimally invasive procedures and breakthrough cardiovascular technologies. - Key studies include the SELUTION DeNovo trial comparing sirolimus-eluting balloons with provisional stenting versus systematic drug-eluting stent implantation for coronary lesions. - Novel approaches featured include intravascular lithotripsy for calcified coronary disease, AI-enabled ECG interpretation for STEMI patients, and advanced transcatheter valve replacement technologies. - Long-term follow-up data from landmark trials like PARTNER 3 will provide seven-year outcomes for transcatheter aortic valve replacement in low-risk patients.
- The Cardiovascular Research Foundation's Technology & Heart Failure Therapeutics (THT) 2025 conference will feature multiple late-breaking clinical trials across four dedicated sessions. - Key studies include novel treatments such as robotic heart transplant techniques, interatrial shunting for different types of heart failure, and innovative fluid management systems. - Notable trials will present data on tirzepatide in HFpEF, cardiac microcurrent therapy, and digital platforms for optimizing heart failure treatment guidelines.
- TCT 2024 will feature 25 late-breaking clinical trials, presenting novel interventions, drugs, and techniques for cardiovascular disease treatment. - The EARLY TAVR trial examines transcatheter aortic valve replacement for asymptomatic severe aortic stenosis, potentially changing treatment paradigms. - The CLEAR SYNERGY trial investigates colchicine and spironolactone's impact on myocardial infarction patients, offering insights into anti-inflammatory therapies. - TRISCEND II will compare transcatheter valve replacement with optimal medical therapy for severe tricuspid regurgitation, addressing a critical unmet need.
- Philips has enrolled the first patient in the DEFINE GPS trial, a global study investigating if iFR measurements co-registered on angiograms improve outcomes in coronary interventions compared to standard angiography alone. - The landmark study will include up to 3,200 participants across 100 sites worldwide, making it one of the largest studies ever sponsored by Philips to address the 20-30% of patients who experience recurring chest pain after PCI procedures. - Led by Dr. Allen Jeremias and Dr. Gregg Stone, the trial aims to determine whether identifying and treating residual ischemia through routine iFR assessment can enhance patient survival and potentially change the current standard of care in PCI.
